Why It Matters
Idaho’s attorney general has signed onto a multistate petition asking federal regulators to treat mifepristone — the drug used in medication abortions — as a waterway pollutant. The effort, coordinated across 14 Republican-led states, could open new federal regulatory avenues targeting the abortion pill beyond the courts.
What Happened
Fourteen Republican state attorneys general sent a letter last Friday to EPA Administrator Lee Zeldin asking the agency to formally classify mifepristone as a water contaminant. The signatories include the top law enforcement officers of Alabama, Alaska, Arkansas, Florida, Idaho, Indiana, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Oklahoma, South Carolina, and Texas.
Separately, Republican Rep. Chris Smith of New Jersey led a concurrent effort on Capitol Hill, gathering signatures from 18 other GOP members of Congress on a parallel letter making the same request to the EPA. In total, 19 congressional Republicans joined that effort.
The attorneys general described the drug’s presence in water systems as “a growing threat to the country’s waterways,” casting the push as one rooted in environmental protection concerns.
Scientific and Regulatory Background
Environmental health scientists have found no evidence that mifepristone present in wastewater poses a danger to human health or ecosystems. That conclusion is not new — the FDA’s Center for Drug Evaluation and Research reached a similar finding back in 1996, determining at that time that harmful environmental effects from the drug were not expected.
Nevertheless, efforts to scrutinize the drug’s environmental footprint have intensified at the state level. During 2025 alone, lawmakers in seven states put forward nine separate bills raising questions about the effects of medication abortion on water supplies and surrounding environments.
By the Numbers
- 14 state attorneys general signed the letter to the EPA
- 19 GOP members of Congress submitted a parallel request
- 9 bills across 7 states in 2025 addressed medication abortion’s alleged environmental effects
- Medication abortion made up nearly two-thirds of all clinician-provided abortions in states without bans as of 2023
- The FDA first evaluated mifepristone’s environmental profile in 1996
Zoom Out
The EPA petition lands while litigation over mifepristone’s availability continues to wind through the courts. The U.S. Supreme Court ruled last month to keep telehealth prescribing access in place pending the Fifth Circuit Court of Appeals’ decision in Louisiana v. Food and Drug Administration. That ruling leaves the drug’s long-term regulatory status unresolved.
Abortion opponents are now pursuing restrictions through multiple channels at once — litigation, state legislation, and federal administrative petitions. Mifepristone has become a focal point because medication abortion now accounts for close to two-thirds of all abortions performed in states where the procedure is legal, making the drug central to the broader policy debate in the post-Dobbs landscape.
Idaho enforces a near-total abortion ban and has consistently joined multistate conservative coalitions on related federal questions, making the attorney general’s participation in this effort consistent with the state’s established policy positions.
What’s Next
The EPA has not announced any response to the petition, and no timeline for agency review has been made public. Should the EPA move to formally classify mifepristone as a water contaminant, that designation would likely trigger additional restrictions on the drug’s production, distribution, and disposal — and would almost certainly face immediate legal challenges from abortion-rights advocates.
The Fifth Circuit’s eventual ruling in the Louisiana case will carry significant weight, potentially reshaping both the legal status of mifepristone and the broader regulatory environment surrounding medication abortion nationwide.
About the Author
